Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › mesothelioma

Mesothelioma

Part of Adenoma

2 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for mesothelioma

52 trials tracked for mesothelioma: 7 in phase 3 or 4 and 6 with published results. The most-cited published study has 1189 citations.

52Trials tracked
7Phase 3 & 4
0Recruiting
6With published results
Phase distribution
Phase 3 7 Phase 2 34 Phase 1 10 Other / NA 1
  1. Phase 3 Study of Nivolumab Combined With Ipilimumab Versus Pemetrexed and Cisplatin or Carboplatin as First Line Therapy in Unresectable Pleural Mesothelioma Patients Completed · 1,189 cited
  2. Phase 3 Suberoylanilide Hydroxamic Acid (Vorinostat, MK-0683) Versus Placebo in Advanced Malignant Pleural Mesothelioma (MK-0683-014) Completed · 220 cited
  3. Phase 3 Early Palliative Care With Standard Care or Standard Care Alone in Improving Quality of Life of Patients With Incurable Lung or Non-colorectal Gastrointestinal Cancer and Their Family Caregivers Completed · 129 cited
  4. Phase 3 Pembrolizumab in Patients With Advanced Malignant Pleural Mesothelioma Completed · 101 cited
  5. Phase 3 Ph 2/3 Study in Subjects With MPM to Assess ADI-PEG 20 With Pemetrexed and Cisplatin Completed · 50 cited
  6. Phase 3 BEAT-meso: Bevacizumab and Atezolizumab in Malignant Pleural Mesothelioma Completed · 5 cited
Show 44 more trials
  1. Phase 3 PembROlizuMab Immunotherapy Versus Standard Chemotherapy for Advanced prE-treated Malignant Pleural Mesothelioma Completed
  2. Phase 2 Pemetrexed Disodium/Observation in Treating Patients W/ Malignant Pleural Mesothelioma w/Out Progressive Disease After 1st Line Chemotherapy Completed
  3. Phase 2 Nintedanib in Treating Patients With Malignant Pleural Mesothelioma That Is Recurrent Completed
  4. Phase 2 A Study of Immunotherapy Drugs Nivolumab and Ipilimumab in Patients w/Resectable Malignant Peritoneal Mesothelioma Completed
  5. Phase 2 Dasatinib in Treating Patients With Previously Treated Malignant Mesothelioma Completed
  6. Phase 2 Cisplatin, Pemetrexed and Bevacizumab for Untreated Malignant Mesothelioma Completed
  7. Phase 2 Phase II MEDI4736 in Combination With Chemotherapy for First-Line Treatment of Unresectable Mesothelioma Completed
  8. Phase 2 Pilot Study of Bisphosphonate Therapy (Zoledronic Acid) in Patients With Malignant Mesothelioma (UAB 0901) Completed
  9. Phase 2 Pazopanib in Treating Patients With Malignant Pleural Mesothelioma Completed
  10. Phase 2 Sunitinib in Treating Patients With Advanced Malignant Pleural Mesothelioma Completed
  11. Phase 2 Study of Pemetrexed in Mesothelioma and Lung Cancer Patients With Fluid Around the Lungs or Abdomen Completed
  12. Phase 2 Anti-TGF Monoclonal Antibody (GC1008) in Relapsed Malignant Pleural Mesothelioma Completed
  13. Phase 2 Olaparib in People With Malignant Mesothelioma Completed
  14. Phase 2 Phase II Trial of Alisertib (MLN8237) in Salvage Malignant Mesothelioma Completed
  15. Phase 2 SS1P and Pentostatin Plus Cyclophosphamide for Mesothelioma Completed
  16. Phase 2 Phase II Anetumab Ravtansine as 2nd Line Treatment for Malignant Pleural Mesothelioma (MPM) Completed
  17. Phase 2 Pemetrexed Plus Gemcitabine or Carboplatin for Patients With Advanced Malignant Pleural Mesothelioma Completed
  18. Phase 2 Treatment of Peritoneal Cancer With Surgery, Perfused Heated Cisplatin and Chemotherapy Completed
  19. Phase 2 Cediranib Maleate in Treating Patients With Malignant Mesothelioma That Cannot Be Removed By Surgery Completed
  20. Phase 2 Transarterial Chemoperfusion: Cisplatin, Methotrexate, Gemcitabine for Unresectable Pleural Mesothelioma Completed
  21. Phase 2 Study of the EZH2 Inhibitor Tazemetostat in Malignant Mesothelioma Completed
  22. Phase 2 S0509 - AZD2171 in Treating Patients With Malignant Pleural Mesothelioma That Cannot Be Removed By Surgery Completed
  23. Phase 2 Phase II Study of IMC-A12 in Patients With Mesothelioma Who Have Been Previously Treated With Chemotherapy Completed
  24. Phase 2 Eloxatin® Plus Gemcitabine Chemotherapy for Mesothelioma Completed
  25. Phase 2 Stereotactic Body Radiation Therapy and Avelumab Immunotherapy for Treatment of Malignant Mesothelioma Completed
  26. Phase 2 αDC1 Vaccine + Chemokine Modulatory Regimen (CKM) as Adjuvant Treatment of Peritoneal Surface Malignancies Completed
  27. Phase 2 Erlotinib Hydrochloride in Treating Patients With Malignant Peritoneal Mesothelioma Completed
  28. Phase 2 Pembrolizumab in Treating Patients With Malignant Mesothelioma Completed
  29. Phase 2 S0722: Everolimus in Treating Patients With Pleural Malignant Mesothelioma That Cannot Be Removed By Surgery Completed
  30. Phase 2 HIPEC for Peritoneal Carcinomatosis Completed
  31. Phase 2 A Trial of Niraparib in BAP1 and Other DNA Damage Response (DDR) Deficient Neoplasms (UF-STO-ETI-001) Completed
  32. Phase 2 PXD101 as Second-Line Therapy in Treating Patients With Malignant Mesothelioma of the Chest That Cannot Be Removed By Surgery Completed
  33. Phase 2 Study of the Efficacy and Safety of the Bintrafusp Alfa in Previously Treated Advanced Malignant Pleural Mesothelioma Completed
  34. Phase 2 18F-FSPG PET/CT for Cancer Patients on Therapy Completed
  35. Phase 2 MEDI4736 Or MEDI4736 + Tremelimumab In Surgically Resectable Malignant Pleural Mesothelioma Completed
  36. Phase 1 Mesothelin-Targeted Immunotoxin LMB-100 in Combination With Tofacitinib in Persons With Previously Treated Pancreatic Adenocarcinoma, Cholangiocarcinoma and Other Mesothelin Expressing Solid Tumors Completed
  37. Phase 1 Vaccine Therapy and GM-CSF in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndromes, Non-Small Cell Lung Cancer, or Mesothelioma Completed
  38. Phase 1 A Study to Investigate 14C-bemcentinib in Healthy Male Subjects Completed
  39. Phase 1 Effects of Itraconazole and Rifampin on the Blood Tazemetostat Levels Completed
  40. Phase 1 CAR T Cells in Mesothelin Expressing Cancers Completed
  41. Phase 1 Mesothelin-Targeted Immunotoxin LMB-100 in People With Malignant Mesothelioma Completed
  42. Phase 1 Arginase Inhibitor INCB001158 as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors Completed
  43. Phase 1 A Study of Pembrolizumab in Combination With Cisplatin and Pemetrexed in Advanced Malignant Pleural Mesothelioma (MPM) (MK-3475-A17) Completed
  44. Phase 1 Phase I Dose-Escalation Study Of Azacitidine In Combination With Temozolomide Completed

Showing the 50 most-cited and recently-updated of 52 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Meta-analysis finds immunotherapy improves survival in mesothelioma
Pulmonology & Critical Care Meta-analysis
Meta-analysis finds immunotherapy improves survival in mesothelioma Immunotherapy boosts survival time for mesothelioma patients across all treatment lines
This meta-analysis of 2549 patients with mesothelioma found that immunotherapy significantly improved overall survival (HR 0.78, p=0.0005). …
New research shows immunotherapy helps mesothelioma patients live longer, offering hope where few options existed before.
May 8, 2026
Meta-analysis identifies germline susceptibility loci for rare cancers including MDS and GIST
Genetics & Precision Medicine Cohort
Meta-analysis identifies germline susceptibility loci for rare cancers including MDS and GIST Genes linked to rare cancers found in large study of over 480,000 people
This meta-analysis of observational cohorts from over 480,000 individuals identified novel germline susceptibility loci for rare cancers.
A huge study of over 480,000 people found new genes that raise the risk of several rare cancers, offering clues for families and doctors.
medRxiv Apr 22, 2026